Mode
Text Size
Log in / Sign up
N/A N=82 Treatment

Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region

Lax Skin

Enrolled (actual)
82
Serious AEs
3.7%
Results posted
Jul 2022
Primary outcome: Primary: Day 180 Number of Participants With Improvement Measured By Independent Photographic Review — 6; 52 Participants — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Renuvion APR Device (Device)
Age
Adult, Older Adult · 35+ yrs
Sex
All
Sponsor
Apyx Medical
Primary completion
Feb 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Day 180 Number of Participants With Improvement Measured By Independent Photographic Review
6; 52 <0.0001 sig
PRIMARY
Subject Reported Pain - None to Moderate
13; 62

Summary

This is a prospective, multi-center, multi-phase, evaluator-blinded study of subjects undergoing a procedure with the Renuvion APR Device to improve the appearance of lax tissue in the neck and submental region.

Eligibility Criteria

Inclusion Criteria

  • Male or female subjects 35-65 years of age (inclusive).
  • Healthy as determined by the investigator examining the subject.
  • Seeking improvement of the appearance of lax tissue in the neck and submental region.
  • Females of childbearing potential who are sexually active must be willing to use an approved method of birth control during study participation.
  • Willing and able to comply with protocol requirements, including obtaining study-required images/photos and assessments, and returning for follow-up visits.
  • Willing to release rights for the use of study photos, including in potential publication.
  • Understands and accepts the obligation not to have significant weight loss or weight gain (≥8 pounds) post the treatment, and for the duration of participation in the study.
  • Willing to abstain from the use of blood thinners (including, but not limited to, Coumadin, NSAIDS, Ibuprofen, vitamin K, other) for 2 weeks (14 days) prior to the procedure.
  • Willing to abstain from smoking, vaping, or the use of e-cigarettes for 1 year prior to and for the entire duration of participation in the study.
  • Willing to abstain from the use of marijuana for 2 weeks prior to and for the duration of participation in the study.
  • Able to read, understand, sign and date the informed consent document (English only).

Exclusion Criteria

  • Pregnant or lactating.
  • Pregnancy within 12 months prior to screening.
  • Use within 24 hours preceding surgery of ibuprofen, acetaminophen, any other analgesics, anti-inflammatory products, or any products including herbals and supplements that could interfere with the clinical assessments of this study (other than drugs used for anesthesia).
  • Allergy to tumescent anesthetic (lidocaine/epinephrine).
  • Excessive subcutaneous fat in the treatment area (as determined by the treating investigator).
  • Active systemic or local skin disease that may alter wound healing.
  • Significant or uncontrolled medical condition that, in the opinion of the investigator, participation in the study may compromise the patient's health.
  • Severe solar elastosis.
  • History of autoimmune disease (excluding Hashimoto's thyroiditis).
  • Known hypersensitivity or adverse reaction to anesthetics.
  • Known susceptibility to keloid formation or hypertrophic scarring.
  • Cancerous or pre-cancerous lesions in the area to be treated.
  • History or current diagnosis of cancer of any type (excluding skin cancer).
  • History of uncontrolled cardiovascular disease (i.e. myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other).
  • History, or current bleeding disorders (i.e. hemophilia or von Willebrand disease), or anticipated treatment with prescription anticoagulants.
  • Possesses a surgically implanted electronic device (i.e. pacemaker).
  • History of AIDs/HIV.
  • Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years.
  • Chronic hypoxia or dependence on supplemental oxygen.
  • Participation in any other investigational study within 30 days prior to consent.
  • Any surgical or transdermal neck/submental aesthetic procedures or plans to undergo any other aesthetic procedure during study participation. Such procedures include, but are not limited to, submentoplasty, liposuction, ultrasound, cryolipolysis, radiofrequency, and laser.
  • History of or current injury to the head and neck or any area of the body being treated as a part of this study.
  • Presence of more than mild platysmal banding as per the Geister, et al Validated Assessment Scale for Platysmal Bands.
  • Subject requiring removal of adipose tissue prior index procedure.
  • A family member of the investigator or sponsor; an employee of the investigator or sponsor.
  • Subject who, in the opinion of the investigator, is not an appropriate candidate for the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04146467). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search